MDGL - Company ID 0001157601
The table below shows MADRIGAL PHARMACEUTICALS, INC.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$167.44M | -$88.89M | -$149.16M | -$84.07M | -$49.91M | -$43.43M |
| Capital expenditure | $3.85M | $0.00 | $357.00K | $35.00K | $52.00K | $44.00K |
| Investing cash flow | $192.19M | $163.88M | $98.05M | -$186.86M | $55.93M | -$33.46M |
| Dividends paid | - | - | - |
MADRIGAL PHARMACEUTICALS, INC. reported operating cash flow of -$189.55M for fiscal year 2025. That is up 58.4% from -$455.57M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$17.61M (FY 2016) to -$189.55M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $2.33M | $8.64M | $573.71M | $52.69M | $0.00 | $67.09M |